Skip to content

Chinese Multi-provincial Cohort Study-Beijing Project

Chinese Multi-provincial Cohort Study-Beijing Project

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04253054
Acronym
CMCS-Beijing
Enrollment
3000
Registered
2020-02-05
Start date
2020-09-07
Completion date
2021-03-31
Last updated
2020-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging Problems, Cardiovascular Diseases, Cardiovascular Risk Factor, Sleep, Smell Disorder

Brief summary

The Chinese Multi-provincial Cohort Study (CMCS)-Beijing project is a sub-study in CMCS participants from Beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. Exam 0 to Exam 3 have been conducted during 1992 to 2012. Exam 4 is scheduled in 2020.

Interventions

OTHERCardiovascular risk factors

Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles

OTHERAging related health problems

Aging related health problems

Sponsors

Beijing Institute of Heart, Lung and Blood Vessel Diseases
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Participants from CMCS-Beijing * sign the informed consent

Exclusion criteria

* participanting in clinical trials

Design outcomes

Primary

MeasureTime frameDescription
All fatal and nonfatal acute coronary and stroke eventsFrom date of enrollment until the date of first documented event or date of cardiovascular death, whichever came first, assessed at least 5 yearsAcute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths. Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.

Secondary

MeasureTime frameDescription
New-onset of coronary eventsFrom date of enrollment until the date of first documented event or date of CHD death, whichever came first, assessed at least 5 yearsAcute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths.
New-onset of strokeFrom date of enrollment until the date of first documented event or date of stroke death, whichever came first, assessed at least 5 yearsAcute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.
Olfactory DisordersFrom date of enrollment until date of first documented event, assessed at least 5 yearsOlfactory Disorders
Cognitive dysfunctionFrom date of enrollment until date of first documented event, assessed at least 5 yearsCognitive dysfunction
Valvular diseaseFrom date of enrollment until the date of first documented event or date of valvular disease death, whichever came first, assessed at least 5 yearsValvular disease
Total deathFrom date of enrollment until date of death from all cause, assessed at least 5 yearsAll cause death

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026